http://purl.org/np/RAflwB6Pey... RAflwB6Pey

links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance

http://www.w3.org/ns/prov#wasAttributedTo wasAttributedTo

https://orcid.org/0000-0002-3668-2627 Elif Ozkan

Elif Ozkan

2022-10-10T14:39:40.187Z

http://purl.org/np/RAflwB6Pey... RAflwB6Pey

links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance

http://www.w3.org/ns/prov#generatedAtTime generatedAtTime

2022-10-10T14:39:40.187124

Elif Ozkan

2022-10-10T14:39:40.187Z

http://purl.org/np/RAflwB6Pey... RAflwB6Pey

links a nanopublication to its provenance http://www.nanopub.org/nschema#hasProvenance provenance

http://www.w3.org/ns/prov#wasQuotedFrom wasQuotedFrom

REPATHA is indicated in adults with established cardiovascular disease to reduce the risk of myocardial infarction, stroke, and coronary revascularization. It is an adjunct to diet, alone or in combination with other low-density lipoprotein cholesterol (LDL-C)-lowering therapies, to reduce LDL-C. In adults with primary hyperlipidemia, including heterozygous familial hypercholesterolemia (HeFH)

Elif Ozkan

2022-10-10T14:39:40.187Z